Get the Stockscreener App
242.43
1.55%
3.69
Pre-market:
241.71
-0.72
-0.30%
Alnylam Pharmaceuticals Inc stock is traded at $242.43, with a volume of 572.03K.
It is up +1.55% in the last 24 hours and down -8.85% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$238.74
Open:
$241.57
24h Volume:
572.03K
Relative Volume:
0.90
Market Cap:
$31.38B
Revenue:
$2.25B
Net Income/Loss:
$-278.16M
P/E Ratio:
-111.72
EPS:
-2.17
Net Cash Flow:
$-42.59M
1W Performance:
-2.73%
1M Performance:
-8.85%
6M Performance:
-7.37%
1Y Performance:
+65.31%
1-Day Range:
$240.39
$246.37
1-Week Range:
$230.79
$252.84
52-Week Range:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Alnylam Pharmaceuticals’ SWOT analysis: strong data bolsters $8B amvuttra potential - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $280.00 at JPMorgan Chase & Co. - Defense World
Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews - Benzinga
Alnylam Reveals Latest CNS Therapeutics Strategy at Upcoming Stifel Forum - StockTitan
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum - Business Wire
Alnylam gearing up for Phase 3 trial of nucresiran in FAP late this year - FAP News Today
U.S. Transthyretin Amyloidosis Market Projected To Witness Substantial Growth, 2025-2032:Alnylam - EIN News
What is Zacks Research’s Estimate for ALNY Q1 Earnings? - Defense World
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Mutual of America Capital Management LLC - Defense World
FY2027 Earnings Forecast for ALNY Issued By Zacks Research - Defense World
Oppenheimer & Co. Inc. Has $404,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
(ALNY) Proactive Strategies - Stock Traders Daily
Alnylam Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by IFP Advisors Inc - Defense World
Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals CSO Kevin Fitzgerald sells shares worth $669,303 By Investing.com - Investing.com Australia
Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced - Simply Wall St
Principal Financial Group Inc. Reduces Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Alnylam Announces Retirement of Board Member, Dr. Phillip A. Sharp - citybiz
Alnylam Pharmaceuticals Announces Retirement of Co-Founder Dr. Phillip A. Sharp - GuruFocus.com
Alnylam co-founder Dr. Sharp to retire from board in May - Investing.com India
Will Alnylam's Scientific Direction Change As Nobel Prize Winner Steps Down From Board? - StockTitan
Alnylam Pharmaceuticals CEO Yvonne Greenstreet sells $700,893 in stock By Investing.com - Investing.com Australia
Alnylam Pharmaceuticals CEO Yvonne Greenstreet sells $700,893 in stock - Investing.com India
Alnylam Pharmaceuticals CSO sells shares for $119,877 - Investing.com
Alnylam Pharmaceuticals CFO sells $192,389 in stock By Investing.com - Investing.com UK
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
H.C. Wainwright maintains $500 target on Alnylam stock - Investing.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Truist Financial Corp - Defense World
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Allianz Asset Management GmbH - MarketBeat
Proficio Capital Partners LLC Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
National Pension Service Sells 36,876 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Y Intercept Hong Kong Ltd Purchases Shares of 4,516 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Chardan Capital - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Needham & Company LLC - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $6.85 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Los Angeles Capital Management LLC Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Illinois Municipal Retirement Fund Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
RNAi Therapeutics and Technology Market Top Companies Study - openPR
William Blair Reaffirms Outperform Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - Defense World
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down - MSN
William Blair Reiterates "Outperform" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Biopharmaceutical index drops in 2024, but starts new year on a rebound - BioWorld Online
Alnylam Pharmaceuticals: Balancing Promising Pipeline with Competitive Challenges and Strategic Uncertainties - TipRanks
Investor Network: Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire
Equities Analysts Issue Forecasts for ALNY Q1 Earnings - MarketBeat
HC Wainwright Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
ALNYAlnylam Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 04 '25 |
Sale |
241.15 |
844 |
203,532 |
13,501 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Mar 03 '25 |
Sale |
243.78 |
471 |
114,820 |
28,011 |
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Mar 03 '25 |
Sale |
243.79 |
1,749 |
426,384 |
25,350 |
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Mar 04 '25 |
Sale |
241.05 |
808 |
194,766 |
24,542 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Mar 03 '25 |
Sale |
243.78 |
1,264 |
308,141 |
47,751 |
| Greenstreet Yvonne | Chief Executive Officer |
Mar 03 '25 |
Sale |
243.79 |
3,877 |
945,165 |
98,635 |
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):